21.34
price up icon0.09%   0.02
after-market アフターアワーズ: 21.34
loading
前日終値:
$21.32
開ける:
$21.46
24時間の取引高:
1.97M
Relative Volume:
1.00
時価総額:
$3.60B
収益:
$890.53M
当期純損益:
$30.57M
株価収益率:
118.56
EPS:
0.18
ネットキャッシュフロー:
$80.53M
1週間 パフォーマンス:
-9.58%
1か月 パフォーマンス:
-17.89%
6か月 パフォーマンス:
+28.48%
1年 パフォーマンス:
+38.75%
1日の値動き範囲:
Value
$20.87
$21.48
1週間の範囲:
Value
$20.02
$21.86
52週間の値動き範囲:
Value
$13.40
$26.65

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
名前
Acadia Pharmaceuticals Inc
Name
セクター
Healthcare (1147)
Name
電話
858-558-2871
Name
住所
12830 EL CAMINO REAL, SAN DIEGO
Name
職員
654
Name
Twitter
@acadiapharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
ACAD's Discussions on Twitter

ACAD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
21.34 3.60B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-21 アップグレード Deutsche Bank Hold → Buy
2025-02-11 開始されました Deutsche Bank Hold
2025-01-03 ダウングレード Guggenheim Buy → Neutral
2024-10-10 再開されました Raymond James Mkt Perform
2024-08-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-06-27 開始されました BMO Capital Markets Outperform
2024-03-12 ダウングレード Mizuho Buy → Neutral
2024-03-12 繰り返されました Needham Buy
2024-01-30 開始されました Robert W. Baird Outperform
2024-01-24 アップグレード Needham Hold → Buy
2023-12-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2023-12-14 ダウングレード Deutsche Bank Buy → Hold
2023-12-13 開始されました Citigroup Buy
2023-12-12 開始されました Deutsche Bank Buy
2023-11-06 アップグレード Mizuho Neutral → Buy
2023-10-17 開始されました UBS Buy
2023-10-10 アップグレード JP Morgan Neutral → Overweight
2023-01-03 アップグレード Guggenheim Neutral → Buy
2022-11-04 ダウングレード Goldman Neutral → Sell
2022-11-01 開始されました Loop Capital Hold
2022-08-08 ダウングレード Citigroup Buy → Neutral
2022-08-05 ダウングレード Citigroup Buy → Neutral
2022-06-21 ダウングレード Jefferies Buy → Underperform
2022-06-16 アップグレード Jefferies Hold → Buy
2022-03-16 アップグレード Canaccord Genuity Hold → Buy
2022-02-09 アップグレード H.C. Wainwright Neutral → Buy
2022-01-05 アップグレード Citigroup Neutral → Buy
2021-12-21 ダウングレード Guggenheim Buy → Neutral
2021-11-01 アップグレード Guggenheim Neutral → Buy
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-06-10 開始されました Berenberg Hold
2021-04-07 ダウングレード H.C. Wainwright Buy → Neutral
2021-04-06 ダウングレード Canaccord Genuity Buy → Hold
2021-04-06 ダウングレード Goldman Buy → Neutral
2021-04-06 ダウングレード Jefferies Buy → Hold
2021-04-06 ダウングレード Mizuho Buy → Neutral
2021-04-05 ダウングレード Raymond James Outperform → Mkt Perform
2021-03-10 ダウングレード BofA Securities Buy → Neutral
2021-03-09 ダウングレード Citigroup Buy → Neutral
2021-03-09 ダウングレード Guggenheim Buy → Neutral
2021-03-09 繰り返されました H.C. Wainwright Buy
2021-03-09 ダウングレード Raymond James Strong Buy → Outperform
2021-03-09 ダウングレード Stifel Buy → Hold
2020-12-16 開始されました Mizuho Buy
2020-11-16 アップグレード Raymond James Outperform → Strong Buy
2020-08-25 開始されました Raymond James Outperform
2020-08-20 開始されました Morgan Stanley Overweight
2020-07-07 アップグレード Stifel Hold → Buy
2020-04-16 開始されました Jefferies Buy
2020-03-31 アップグレード Goldman Neutral → Buy
2020-03-06 開始されました Citigroup Buy
2019-12-16 開始されました Guggenheim Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-01 開始されました RBC Capital Mkts Outperform
2019-09-13 アップグレード SVB Leerink Mkt Perform → Outperform
2019-09-10 アップグレード Canaccord Genuity Hold → Buy
2019-07-23 繰り返されました Needham Buy
2018-12-10 開始されました Canaccord Genuity Hold
2018-09-21 アップグレード Piper Jaffray Neutral → Overweight
2018-08-09 繰り返されました Stifel Hold
2018-08-07 開始されました Stifel Hold
2018-08-06 ダウングレード Piper Jaffray Overweight → Neutral
2017-10-06 再開されました Goldman Neutral
すべてを表示

Acadia Pharmaceuticals Inc (ACAD) 最新ニュース

pulisher
02:25 AM

Why ACADIA Pharmaceuticals Inc. stock could be next big winner2025 Dividend Review & Entry Point Confirmation Signals - newser.com

02:25 AM
pulisher
Sep 29, 2025

News impact scoring models applied to ACADIA Pharmaceuticals Inc.July 2025 Technicals & Fast Momentum Stock Entry Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

JP Morgan Updates ACADIA Pharmaceuticals (ACAD) Analyst Rating | - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $33.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Will ACADIA Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWeekly Investment Report & Verified Swing Trading Watchlist - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps - MSN

Sep 28, 2025
pulisher
Sep 28, 2025

What analysts say about ACADIA Pharmaceuticals Inc stockMomentum Stock Picks & Budget Friendly Growth - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

What drives ACADIA Pharmaceuticals Inc stock priceAnalyst Downgrades & Market Crushing Stock Picks - Early Times

Sep 27, 2025
pulisher
Sep 27, 2025

What machine learning models say about ACADIA Pharmaceuticals Inc.Index Update & Long-Term Growth Plans - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Acadia drops development of carbetocin in PWS - The Pharma Letter

Sep 26, 2025
pulisher
Sep 25, 2025

Acadia to stop development of rare disease therapy after trial failure - ET Pharma

Sep 25, 2025
pulisher
Sep 25, 2025

ACADIA Pharmaceuticals Hits Day Low of $20.03 Amid Price Pressure - Markets Mojo

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals stock price target maintained by BMO after trial miss - Investing.com Canada

Sep 25, 2025
pulisher
Sep 25, 2025

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - sharewise.com

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says - MarketScreener

Sep 25, 2025
pulisher
Sep 25, 2025

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $35 - 富途牛牛

Sep 25, 2025
pulisher
Sep 25, 2025

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating - MarketScreener

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia, Harmony record late-stage rare disease failures - pharmaphorum

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - BioSpace

Sep 25, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock price target lowered to $35 at TD Cowen - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Gives Up In PWS After Another ACP-101 Phase III Miss - insights.citeline.com

Sep 24, 2025
pulisher
Sep 24, 2025

Oppenheimer cuts Acadia Pharmaceuticals stock price target after failed study By Investing.com - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno - Fierce Pharma

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals: Reeling After PWS FailureDowngrading To Hold (NASDAQ:ACAD) - Seeking Alpha

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint By Investing.com - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

BMO Capital reiterates Acadia Pharmaceuticals stock rating despite trial failure - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq

Sep 24, 2025
pulisher
Sep 24, 2025

ACAD: Latest Developments and Market Insights - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Faces Setback After Phase 3 Trial Results - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

ACADIA Pharmaceuticals (ACAD): Needham Lowers Price Target, Maintains Buy Rating | ACAD Stock News - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down Following Analyst Downgrade - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia to scrap Prader-Willi drug after study setback - BioPharma Dive

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Needham & Company LLC Has Lowered Expectations for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock unchanged as BofA maintains Neutral rating By Investing.com - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia, with a failed phase III, drops Prader-Willi candidate - BioWorld MedTech

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia’s phase 3 trial for Prader-Willi syndrome drug fails to meet goals - Investing.com Australia

Sep 24, 2025
pulisher
Sep 24, 2025

Traders Buy Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD) - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Experiences Significant Drop in St - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target - TipRanks

Sep 24, 2025
pulisher
Sep 24, 2025

Leerink on Acadia (ACAD): 'Despite the news, we still like the stock' - StreetInsider

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Scraps Prader-Willi Drug After Late-Stage Failure - BioSpace

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Shares Dip After Trial Disappointm - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Lithium Americas, Oracle, Acadia Pharma: Trending Tickers - Yahoo Finance

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma (ACAD) Shares Plunge After Prader-Willi Drug Setba - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Stifel maintains Hold rating on Acadia Pharmaceuticals stock after drug failure By Investing.com - Investing.com South Africa

Sep 24, 2025
pulisher
Sep 24, 2025

ACAD Stock Falls as Phase 3 Trial Results Disappoint - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Stifel maintains Hold rating on Acadia Pharmaceuticals stock after drug failure - Investing.com

Sep 24, 2025

Acadia Pharmaceuticals Inc (ACAD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
大文字化:     |  ボリューム (24 時間):